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OBJECTIVE: Residual disease after initial surgery for
ovarian cancer is the strongest prognostic factor for
survival. However, the extent of surgical resection re-
quired to achieve optimal cytoreduction is controversial.
Our goal was to estimate the effect of aggressive surgical
resection on ovarian cancer patient survival.
METHODS: A retrospective cohort study of consecutive
patients with International Federation of Gynecology and
Obstetrics stage IIIC ovarian cancer undergoing primary
surgery was conducted between January 1, 1994, and
December 31, 1998. The main outcome measures were
residual disease after cytoreduction, frequency of radical
surgical resection, and 5-year disease-specific survival.
RESULTS: The study comprised 194 patients, including 144
with carcinomatosis. The mean patient age and follow-up
timewere 64.4 and 3.5 years, respectively. After surgery, 131
(67.5%) of the 194 patients had less than 1 cm of residual
disease (definition of optimal cytoreduction). Considering
all patients, residual disease was the only independent
predictor of survival; the need to perform radical proce-
dures to achieve optimal cytoreduction was not associated
with a decrease in survival. For the subgroup of patients
with carcinomatosis, residual disease and the performance
of radical surgical procedures were the only independent
predictors. Disease-specific survival was markedly im-
proved for patients with carcinomatosis operated on by
surgeons who most frequently used radical procedures
compared with those least likely to use radical procedures
(44% versus 17%, P < .001).
CONCLUSION: Overall, residual disease was the only
independent predictor of survival. Minimizing residual
disease through aggressive surgical resection was bene-
ficial, especially in patients with carcinomatosis.
(Obstet Gynecol 2006;107:77–85)
LEVEL OF EVIDENCE: II-2
In the United States, ovarian cancer is the leadingcause of death from gynecologic malignancy, with
16,210 deaths anticipated to occur in 2005.1 The
majority of women present with advanced intra-
abdominal disease and subsequently low cure rates.
Since Griffiths’2 publication 30 years ago, the extent
of cytoreductive surgery and the amount of residual
disease after primary surgery have been considered
the most important factors influencing the survival of
patients with advanced ovarian cancer. The premise
that low residual disease after primary surgery results
in improved survival rates has held true in nearly
every large retrospective and prospective publication
to date.3,4 Accordingly, the concept of optimal cytore-
duction has evolved over time and now generally
applies to residual lesions no larger than 1 cm in
diameter after primary surgery. Importantly, residual
disease is the only prognostic factor under the control
of the operating surgeon.
Several radical surgical procedures, including intes-
tinal resection,5,6 splenectomy,7 diaphragmatic resec-
tion,8 and hepatic resection,9 have been described as
treatments for advanced ovarian cancer with acceptable
morbidity.10 Nevertheless, Nguyen et al11 found that
only 42–45% of patients primarily treated by a gyneco-
logic oncologist received optimal cytoreduction, despite
a less stringent definition of acceptable residual disease.
This rate was not markedly different when compared
with the rate of optimal cytoreduction achieved by
general obstetricians and gynecologists.
A survey was conducted of the membership of
the Society of Gynecologic Oncologists12 to gain
insight into factors responsible for the infrequency of
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optimal cytoreduction. The sites of disease most fre-
quently noted as precluding optimal cytoreduction
were the diaphragm, bowel, and portal triad. Ironi-
cally, among respondents who achieved optimal cy-
toreduction (defined as residual disease  1 cm) in
less than 50% of their ovarian cancer patients, 45.5%
of the surgeons cited lack of evidence for improved
survival as a primary rationale against performing
aggressive surgical resection.
The philosophy against aggressive surgical resec-
tion stems from the largely untested hypothesis that
the initial extent of advanced disease (or tumor biol-
ogy) ultimately dictates treatment outcomes. There-
fore, when radical procedures are necessary to
achieve optimal cytoreduction, they are unlikely to be
helpful, despite minimizing residual disease. Carcino-
matosis, large-volume ascites, nodal metastasis, upper
abdominal involvement, and high histologic grade
are predictors of survival.13–16 However, the analysis is
confounded because these factors frequently result in
suboptimal cytoreduction. Thus, a critical question
persists: Can aggressive surgical resection improve
survival rates for patients with ovarian tumors? Eisen-
kop and Spirtos10 suggested that aggressive surgical
resection does not necessarily portend a worse prog-
nosis for patients, once the outcome is adjusted for
residual disease. Furthermore, these single-institution
data suggested that extensive surgical efforts do im-
prove overall survival rates.10
This study examined the survival rates in a cohort
of consecutively treated patients with advanced-stage
ovarian cancer. Our surgical group favors aggressive
surgical resection for ovarian cancer. Thus, we tested
the hypothesis that the extent of surgical resection
required for optimal cytoreduction affected ovarian
cancer patient survival.
MATERIALS AND METHODS
Mayo Foundation Institutional Review Board ap-
proval was obtained for this study. All patients who
received a diagnosis of primary epithelial ovarian
cancer between January 1, 1994, and December 31,
1998, were identified from surgical records. Consec-
utive patients undergoing primary surgical explora-
tion with a postoperative diagnosis of epithelial ovar-
ian cancer were included.
Preoperative medical evaluations were per-
formed for all patients, and each was classified by
American Society of Anesthesiologists (ASA) score.
Surgical staging and grading were consistent with the
International Federation of Gynecology and Obstet-
rics (FIGO) standards.17 Only patients with FIGO
stage IIIC ovarian cancer were included in this study.
Patients who underwent surgical exploration at an-
other institution or who received neoadjuvant chemo-
therapy before surgery were excluded from the study.
All patients were scheduled for treatment with first-
line postoperative platinum-based chemotherapy
(paclitaxel or cyclophosphamide for 6–8 courses,
every 3–4 weeks, according to the specific protocols
in effect at the time). Operative reports, hospital and
outpatient notes, the Mayo Clinic Cancer Center
Registry database, and correspondence from referral
institutions were abstracted for relevant clinical data.
Disease status was extracted from surgical explo-
ration notes. Patients were first classified by the extent
of peritoneal dissemination. Those with tumor nod-
ules diffusely covering the majority of the bowel
serosa surfaces and the parietal peritoneum of the
abdomen and pelvis were classified as having carci-
nomatosis. Patients with disease primarily seeding the
mesenteric surfaces or deeper tissues, but not the
remainder of the visceral or parietal peritoneum, were
classified as having mesentery involvement. Indepen-
dent of the extent of peritoneal disease, we further
categorized patients on the basis of tumor involve-
ment with the diaphragm, presence of cul-de-sac
obliteration by the tumor, and the volume of ascites.
For statistical analysis, variables regarding patient
characteristics were recorded in the following man-
ner: 1) age, less than or equal to 65 years old or more
than 65 years old; 2) ASA score 1 or 2 versus 3 or 4;
3) histologic grade 1 or 2 versus 3; and 4) serous
histologic subtype versus all other subtypes. For op-
erative time, we used less than or equal to 150 minutes
or greater than 150 minutes, and the interval from
surgery to chemotherapy had a 28-day cutoff. Resid-
ual disease was noted as follows: 1) no residual disease
(no gross tumor at the completion of surgery); 2)
residual disease smaller than 1 cm; 3) residual disease
of 1–2 cm; and 4) residual disease larger than 2 cm.
Statistical analysis was performed with the 2 analysis
and logistic regression analysis. Disease-specific over-
all survival was measured in all cases. Survival curves
were plotted with the Kaplan-Meier method and
included the log-rank test. The Cox proportional
hazards regression model was used for univariate and
multivariable analyses. Significant variables from the
univariate analysis were included in the multivariable
model. Differences were considered statistically sig-
nificant at P  .05. Statistical software (JMP 5.1; SAS
Institute Inc, Cary, NC) was used for the analysis.
RESULTS
A total of 194 consecutive patients with FIGO stage
IIIC ovarian cancer met the inclusion criteria for our
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study (Table 1). Mean and median follow-up was 3.5
and 2.7 years, respectively (range 0.02–10.5 years).
During the follow-up period, the median number of
procedures was 2 (range 1–11), and the median
number of chemotherapy courses was 3 (range 0–14).
Initial surgery was performed for diagnosis, stag-
ing, and surgical cytoreduction. The majority of pa-
tients had carcinomatosis, diaphragm involvement,
cul-de-sac involvement, and ascites (Table 1). The
mean operative time was 210 minutes (range 40–480
minutes). Optimal cytoreduction (defined as residual
disease  1 cm) was achieved in 67.5% of the patients
(131/194; 95% confidence interval [CI] 60.6–73.7%),
and the 5-year disease-specific overall survival rate
was 35% (68/194; 95% CI 28.7–42.0%). The specific
primary procedures are summarized in Table 2.
Perioperative mortality rate, defined as the per-
centage of patients who died within 30 days of
surgery, was 1.5% (3/194; 95% CI 0.5–4.4%). The
ages of these 3 patients were 75, 76, and 83 years, and
Table 1. Stage IIIC Ovarian Cancer Patient
Characteristics, Tumor Features, and
Initial Operative Findings (n  194)
Characteristics Patients*
Age (y)
Mean (range) 64.4 (24–87)
Median 64
ASA score
1 7 (3.6)
2 87 (44.8)
3 88 (45.4)
4 7 (3.6)
Unknown 5 (2.6)
Tumor features
Grade
1 1 (0.5)
2 13 (6.7)
3 180 (92.8)
Histology
Serous 126 (64.9)
Mucinous 4 (2.1)
Endometrioid 18 (9.3)
Clear cell 7 (3.6)
Transitional cell 3 (1.5)
Mixed 17 (8.8)
Seroanaplastic 17 (8.8)
Mu¨llerian origin 2 (1.0)
Cytology
Positive 178 (91.8)
Negative 16 (8.2)
Residual disease (cm)
None detectable 46 (23.7)
 1 85 (43.8)
1–2 22 (11.3)
 2 41 (21.1)
Extent of disease
Carcinomatosis 144 (74.2)
Diaphragm involvement 137 (70.6)
Mesentery involvement 138 (71.1)
Cul-de-sac involvement 163 (84.0)
Omentum involvement 168 (86.6)
Ascites 160 (82.5)
Mean (range), mL 2,076 (0–12,000)
Median, mL 1,000
ASA, American Society of Anesthesiologists.
* Values are expressed as n (%) unless indicated otherwise.
Table 2. Surgical Procedures Performed
Patients (n  194)
Anatomic Structures and
Surgical Procedures n %
Uterus
Hysterectomy 162 83.5
Already done 25 12.9
Not done 7 3.6
Adnexa
Bilateral 190 97.9
Monolateral 0 0
Biopsy 3 1.5
None 1 0.5
Omentum
Total 171 88.1
Infracolic 11 5.7
Biopsy 9 6
None 3 1.5
Diaphragm
Excision nodules 16 8.2
Stripping peritoneum 6 3.1
Segmental resection 1 0.5
Cauterization 8 4.1
None 163 84.0
Peritoneum
Ablation 7 3.6
General cytoreduction 53 27.3
Cauterization 6 3.1
Excision nodules 21 10.8
None 107 55.2
Pelvic nodes
Systematic lymphadenectomy 75 38.7
Monolateral lymphadenectomy 5 2.6
Sampling 15 7.7
Not done 99 51.0
Para-aortic nodes
Systematic lymphadenectomy 74 38.1
Up to IMA 2 1.0
Sampling 8 4.1
Not done 110 56.7
Stripping pelvic peritoneum 91 46.9
Left colectomy 2 1.0
Transverse colectomy 2 1.0
Right colectomy 3 1.5
Rectosigmoidectomy 47 24.2
Small bowel resection(s) 11 5.7
Partial gastrectomy 2 1.0
Splenectomy 12 6.2
IMA, inferior mesenteric artery.
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the ASA score was 3 in 2 patients and 4 in the other.
None had undergone any aggressive procedure (see
classification below). Nine patients (4.6%) did not re-
ceive chemotherapy because of rapid disease progres-
sion, patient refusal, inadequate performance status, or
perioperative death; all 9 died within 3.5 months of their
surgery date. Based on the intent to treat, these patients
were included in the survival analysis.
Although the extent of disease at presentation
may affect patient outcome, the amount of surgical
resection and subsequent residual disease also influ-
ences survival (Figs. 1A and 1B). We examined the
effects of different patient variables on survival using
the Cox proportional hazards regression model (Ta-
ble 3). Univariate analysis indicated that age, ASA
score, ascites volume, presence of carcinomatosis,
disease involvement of the diaphragm or bowel mes-
entery, and residual disease smaller than 1 cm were
prognostic factors. Multivariate analysis (logistic re-
gression) ultimately showed the only significant pre-
dictor of survival was residual disease. We questioned
whether the disease-specific overall survival rate for
patients with extensive disease was low due to the
infrequency of optimal cytoreduction. Not surpris-
ingly, there was a statistically significant direct corre-
lation (2 test) between suboptimal cytoreduction
(residual disease  1 cm) and the presence of carci-
nomatosis (P  .001), diaphragm involvement (P 
.001), mesentery involvement (P  .001), or ascites
(P .001). This observation confirmed that the extent
of disease affected survival by limiting surgical cytore-
duction, but, after adjusting for residual disease, initial
tumor volume became a minor determinant of overall
survival. Therefore, we hypothesized that patients
requiring aggressive surgical procedures to achieve
optimal residual disease will have a disease-specific
overall survival rate similar to those undergoing rela-
tively less aggressive procedures to achieve the same
amount of residual disease. We examined the survival
rates of just the 131 patients who had optimal cytore-
duction (residual disease  1 cm). If any diaphrag-
matic surgery, bowel resection, splenectomy, or ex-
tensive abdominal peritoneal stripping or resection
was performed, the patients were classified in the
radical surgery group (n  69; 53%). We chose these
procedures because they were likely to result in
resection of gross disease and are often classified as
aggressive treatments. For these reasons, lymphade-
nectomy was not considered radical surgery. Dia-
phragm surgery required specific mobilization of liver
to achieve exposure for partial-thickness resection of
nodules. The remaining patients were classified as
having nonradical surgery (n  62; 47%). The latter
group included patients undergoing hysterectomy,
complete omentectomy, stripping of pelvic perito-
neum, or limited resection of peritoneal-based nod-
ules. Five-year disease-specific overall survival rates
for patients who had aggressive procedures for opti-
mal residual disease were nearly identical to disease-
specific overall survival rates for patients who had
optimal residual disease with less aggressive surgery
(46% versus 47%; log-rank test, P  .80) (Fig. 2).
Therefore, optimal cytoreduction, regardless of the
extent of surgery, appeared to negate the effect of
tumor burden.
To further analyze whether patients undergoing
surgical cytoreduction benefit from radical surgery,
Fig. 1. Residual disease affects survival in patients with
stage IIIC ovarian cancer. A. Survival curves for all patients
(n  194; log-rank test, P  .001). B. Survival curves for
patients with carcinomatosis (n  144; log-rank test, P 
.001).
Aletti. Surgery and Advanced Ovarian Cancer. Obstet Gynecol
2005.
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we examined the subgroup of patients with carcino-
matosis, ie, the highest volume of disease, who under-
went successful optimal cytoreduction (n  82). The
performance of radical surgery was a significant pre-
dictor of improved outcome. For patients with radical
and nonradical surgery, the 5-year disease-specific
overall survival rate was 44% compared with 17%,
respectively (log-rank test, P  .001). In addition to
radical surgery, residual disease, age, ASA score, and
operative time correlated with disease-specific overall
survival rate (Table 4). However, in multivariable
analysis, only residual disease and radical surgery
were independent factors predicting patient survival
(Table 4).
When examining the effect of radical surgery on
all patients with carcinomatosis (n  144), we ob-
served an improved disease-specific overall survival
rate (38% versus 9%; log-rank test, P  .001) favoring
patients who underwent radical procedures versus
nonradical procedures (Fig. 3). This is not unexpected
because we anticipated that patients with unresectable
disease (or prohibitive medical conditions) would be
least likely to undergo radical surgery. Furthermore,
we noted a strong correlation between residual dis-
ease less than 1 cm and radical surgery (P  .001).
However, as demonstrated earlier, when the analysis
was restricted to patients who received optimal cy-
toreduction, a clear benefit to radical surgery was
observed.
We considered factors outside of extent of disease
that might be important in the decision to perform
radical surgery. Radical procedures were performed
at the same rate regardless of age (49% for age  65
years versus 51% for age 65 years; P .45). Patients
with better ASA scores (1 or 2 versus 3 or 4) were
more likely to have aggressive procedures performed
(59% versus 36%, respectively; P  .005), which
implies the overall medical condition of the patient at
least partially influences the decision to perform
aggressive surgery.
We questioned whether better ASA scores con-
tributed to the survival benefit in patients who
underwent radical procedures. We identified a
striking correlation among survival rates and the
Fig. 2. Effect of surgical effort on Kaplan-Meier survival for
patients with stage IIIC ovarian cancer with residual disease
smaller than 1 cm. Patients were categorized by surgery
required for optimal cytoreduction (n  131; log-rank test,
P  .80).
Aletti. Surgery and Advanced Ovarian Cancer. Obstet Gynecol
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Table 3. Cox Proportional Hazards Regression Model for Different Variables in Patients With Stage IIIC
Ovarian Cancer (n  194)
Confidence Limit P
Variable Risk Ratio Lower Upper Univariate Multivariable*
Age ( vs  65 y) 1.65 1.17 2.33 .004 .12
Age (continuous) 1.03 1.02 1.05  .001 .56
ASA (3 or 4 vs 1 or 2) 1.70 1.21 2.41 .002 .79
Ascites ( vs  1,000 mL) 2.30 1.52 3.56 .001 .47
Carcinomatosis (Y vs N) 3.63 2.32 5.97  .001 .50
Diaphragm (Y vs N) 2.43 1.63 3.74  .001 .89
Bowel mesentery (Y vs N) 3.07 2.02 4.82  .001 .99
Residual disease
 1 cm vs 0 cm 3.89 2.27 7.11  .001  .001
1–2 cm vs 0 cm 6.25 3.16 12.61 — —
 2 cm vs 0 cm 13.00 7.14 24.87 — —
Histologic grade (3 vs 1 or 2) 0.97 0.54 1.97 .92 —
Histology (others vs serous) 0.79 0.54 1.12 .77 —
Operative time ( vs  150 min) 0.68 0.48 1.00 .05 .41
Time to chemotherapy ( vs  28 d) 1.00 0.68 1.51 .99 —
ASA, American Society of Anesthesiologists.
* Significant variables for the univariate analysis were included in the multivariable model.
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performance of aggressive procedures in the subset of
patients with carcinomatosis and good performance
status (ASA score  1 or 2; n  72). The 5-year
disease-specific overall survival rate was 46% compared
with 13% for patients with radical and nonradical sur-
geries, respectively (log-rank test, P .001; Fig. 4A). We
restricted the sample population even further by exam-
ining only the patients with residual disease smaller than
1 cm (n 49). In this analysis (patients with carcinoma-
tosis, ASA score 1 or 2, and residual disease 1 cm),
the 5-year disease-specific overall survival rate was
53% versus 30%, favoring the aggressive surgery
group (log-rank test, P  .09; Fig. 4B). Although the
statistical significance of our observations was limited
by the small sample size, these results are suggestive
that the benefit of aggressive surgery on survival rate
may be independent of performance status.
We wished to estimate whether patient outcomes
were affected by a surgeon’s propensity to use radical
procedures during cytoreductive surgery. Surgeons
were classified according to how often they used
radical procedures in the management of patients
with ovarian cancer. We compared the outcomes for
surgeons using radical procedures in more than 70%
of patients and surgeons using radical procedures in
less than 40% of patients (Table 5). There were no
significant differences in patient age, ASA score,
diaphragm or mesentery involvement, or volume of
ascites between groups, confirming a relatively ran-
dom distribution of patients. However, the rate of
optimal resection (residual disease 1 cm) was 84.5%
compared with 51% on the basis of surgeon tendency
to use radical procedures, which clearly highlights the
value of extensive surgical effort. Additionally, our
division of gynecologic surgery shares a uniform
referral base with similar patient demographics, and
we practice at a single institution where each surgeon
has access to identical services and nursing support.
Our analysis indicated that only performance of
radical procedures (81.5% versus 31.0%), residual
disease, and longer overall operative time substan-
tially affected patient outcomes. We noted striking
differences in overall survival for patients treated by
surgeons who frequently used radical procedures (Fig.
Fig. 3. Effect of surgical resection on Kaplan-Meier survival
in patients with stage IIIC ovarian cancer and carcinoma-
tosis (n  144; log-rank test, P  .001).
Aletti. Surgery and Advanced Ovarian Cancer. Obstet Gynecol
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Table 4. Cox Proportional Hazards Regression Model for Patients With Stage IIIC Ovarian Cancer and
Carcinomatosis at the Beginning of the Surgical Procedure (n  144)
Confidence Limit P
Variable Risk Ratio Lower Upper Univariate Multivariable*
Age ( vs  65 y) 1.15 0.80 1.67 .44 —
Age (continuous) 1.02 1.00 1.04 .03 .73
ASA score (3 or 4 vs 1 or 2) 1.62 1.12 2.36 .01 .24
Ascites ( vs  1,000 mL) 1.34 0.81 2.33 .26 —
Diaphragm (Y vs N) 1.11 0.66 1.98 .71 —
Bowel mesentery (Y vs N) 1.64 0.88 3.48 .13 —
Residual disease
 1 cm vs 0 cm 2.55 0.94 10.47  .001  .001
1–2 cm vs 0 cm 4.05 1.36 17.28 — —
 2 cm vs 0 cm 8.26 2.96 34.35 — —
Aggressive surgery (Y vs N) 0.43 0.29 0.62  .001 .047
Histologic grade (3 vs 1 or 2) 1.28 0.67 2.86 .49 .14
Histology (others vs serous) 0.90 0.58 1.34 .60 —
Operative time ( vs  150 min) 0.53 0.36 0.79 .002 .34
Time to chemotherapy ( vs  28 d) 0.95 0.61 1.50 .82 —
ASA, American Society of Anesthesiologists.
* Significant variables from the univariate analysis were included in the multivariable model.
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5). These data were the strongest evidence that ag-
gressive surgical resection affected survival for pa-
tients with similar disease levels.
DISCUSSION
Cytoreductive surgery is a cornerstone of the initial
treatment for patients with advanced ovarian cancer.
The amount of residual disease after primary surgery
is generally considered the most important modifiable
prognostic factor influencing survival of patients with
advanced disease.18 In this retrospective study, we
observed that 1) residual disease was the only inde-
pendent predictor of outcome in patients with stage
IIIC ovarian cancer; 2) radical surgical resection and
residual disease independently affected survival of
patients with the most clinically aggressive disease; 3)
differences among individual surgeons in their ten-
dency to use radical procedures affected overall sur-
vival; and 4) considering those patients with optimal
cytoreduction (residual disease  1 cm), survival was
the same whether they underwent radical or nonradi-
cal surgical procedures.
For stage IIIC ovarian cancer patients, we de-
fined 4 distinct prognostic groups based on residual
disease: 1) complete cytoreduction, 2) residual disease
smaller than 1 cm, 3) residual disease between 1 and
2 cm, and 4) residual disease larger than 2 cm. The
phrase optimal cytoreduction is clinically vague and
disregards the consistent observation that wide differ-
ences in survival exist among patients with no resid-
ual disease compared with patients having 1 or 2 cm
of residual disease. Although many gynecologic on-
cologists still define optimal cytoreduction as residual
disease smaller than 2 cm,12,19 our data support pre-
vious evidence that residual disease of 2 cm has
limited validity and that its use in the definition of
optimal cytoreduction should be avoided. In addition,
care must be taken to prevent confusing the term
optimal (intended as a general prognosticator after
surgery) with the philosophy that optimal equates with
best or is the final goal of cytoreduction. In fact, optimal
cytoreduction is an arbitrary designation and not nec-
essarily indicative of the best prognosis. Clearly, the
true optimal scenario is complete cytoreduction of
visible disease. This should be the goal of cytoreduc-
tive surgery for ovarian cancer whenever feasible,
mitigated only by the limits of resectability and
unacceptable morbidity.
Our results do not deny that tumor biology affects
the patient outcome. However, we believe the most
valid indicator of tumor aggressiveness is the extent of
disease at the initial surgical exploration. Logically,
this affects our ability to achieve optimal cytoreduc-
tion: our data suggest that tumor aggressiveness has a
major effect on survival. The threshold for resectable
disease depends on many factors. Nevertheless, even
for our patients with the most severe disease, 57%
were resected to less than 1 cm residual disease.
Berman20 asserted that it is not understood whether
complete cytoreduction reflects the surgeon’s skill or
the intrinsic biological behavior of the tumor. In fact,
the resectability of such disease, with acceptable
morbidity, does reflect the surgical experience, tech-
nique, excellence in anesthesia, critical care, and
nursing. Given the importance of minimizing residual
disease, forgoing primary cytoreduction on the basis
of the initial tumor extent appears unjustified, at least
for practices commonly using radical procedures in
the surgical management of ovarian cancer.
Confirming a previous report by Eisenkop and
Spirtos,10 we observed no difference in disease-spe-
cific overall survival rates between patients who re-
quired radical surgical procedures to achieve optimal
Fig. 4. Effect of surgical resection on Kaplan-Meier survival
in patients with stage IIIC ovarian cancer with carcinoma-
tosis and ASA score 1 or 2. A. All patients (n  72; log-rank
test, P  .001). B. Subset of patients with residual disease
smaller than 1 cm (n  49; log-rank test, P  .09).
Aletti. Surgery and Advanced Ovarian Cancer. Obstet Gynecol
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cytoreduction and those who were rendered optimal
with nonradical surgery. This further supports the
hypothesis that surgical resection minimizes the im-
pact of tumor dissemination. Our data also suggest
that radical procedures were superior to nonradical
procedures when considering patients with the most
extensive disease. The survival benefits did not ap-
pear to result from differences in age or ASA status,
although we recognize the limitations of our retro-
spective study in evaluating the complex factors of the
decision-making process to use radical procedures.
Our observation that residual disease and radical
surgery independently predicted disease-specific
overall survival rates for patients with carcinomatosis
strongly suggests that extraordinary surgical efforts
positively affect survival for patients with aggressive
ovarian cancer. We have several hypotheses that may
explain this observation. In the radical surgery sub-
group, complete resection of surrounding tissue may
remove gross infiltrative or spreading plaques of
tumor that could be regarded as optimal if left in situ.
Alternatively, the performance of radical procedures
was a marker of surgical thoroughness that pervaded
throughout the case but was difficult to abstract from
operative notes or characterize in general.
Given the consistently observed benefit and the
long-held bias in our specialty for the value of cytore-
ductive surgery, it is unlikely that a randomized trial
could be designed to examine the effect of surgical
effort on survival. In lieu of this, our retrospective
study identified differences in disease-specific overall
survival rates that allowed us to examine the influence
of surgeons’ tendency to use radical procedures on
overall survival. Our data originate from a single
institution with a common referral pattern, identical
intraoperative and postoperative care, and a common
practice of adjuvant chemotherapy, all of which add
credibility to our findings. Even within a group of
surgeons who regularly perform radical procedures to
Fig. 5. Effect of surgeon tendency to perform aggressive
surgery on Kaplan-Meier survival in patients with stage IIIC
ovarian cancer and carcinomatosis (log-rank test, P 
.001).
Aletti. Surgery and Advanced Ovarian Cancer. Obstet Gynecol
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Table 5. Comparison of Variables for 144 Patients With Carcinomatosis When Classified by Tendency of
Surgeons to Use Aggressive Procedures
Surgeons (%)
> 70% Aggressive
Procedures (n  32)
< 40% Aggressive
Procedures (n  61) P (2 Analysis)
Age ( 65 y) 56.0 52.5 .73
ASA score
1 3.0 2.0 .33
2 59.5 40.5 —
3 34.5 52.5 —
4 3.0 5.0 —
Ascites ( 1,000 mL) 73.5 75.0 .91
Diaphragm involvement 84.5 82.0 .87
Mesentery involvement 97.0 85.5 .06
Aggressive procedures 81.5 31.0  .001
Residual disease (cm)
0 9.5 5.0  .001
 1 75.0 46.0 —
1–2 12.5 11.5 —
 2 3.0 37.5 —
Operative time ( 150 min) 94.0 63.5  .001
Histologic grade 3 90.5 92.0 .85
Histology, serous 62.5 72.0 .34
ASA, American Society of Anesthesiologists.
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achieve low residual disease, we observed large dif-
ferences in disease-specific overall survival rates
based on surgeon tendencies. When extrapolated to
practices less likely to use radical procedures, the
differences in survival might be much larger.
Because surgical expertise is one of the defining
hallmarks of a gynecologic oncologist, it would be-
hoove each center, and perhaps each surgeon, to
objectively determine their own rates of surgical
cytoreduction for advanced-stage disease. Obstacles
to success should be honestly examined with the goal
of improving the care of women with ovarian cancer.
Given training, concerted efforts, and a coordinated
approach to adopting new techniques, substantial
improvement in cytoreduction can be achieved, as
recently demonstrated by Chi et al21 at Memorial
Sloan-Kettering Cancer Center. Minimal residual dis-
ease is a critical factor in determining overall survival
and is independent of the radical procedures neces-
sary to achieve this goal, the initial extent of disease,
or the biological aggressiveness of the cancer. We
should not allow ourselves to dismiss this historically
consistent observation without strong evidence that
we can predict a priori which tumors will not benefit
from resection. This untested hypothesis is unjustified
and is unlikely to improve the care of women with
ovarian cancer.
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